<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093976</url>
  </required_header>
  <id_info>
    <org_study_id>0909M72088</org_study_id>
    <nct_id>NCT01093976</nct_id>
  </id_info>
  <brief_title>Marinol in Trichotillomania or Obsessive Compulsive Disorder</brief_title>
  <official_title>An Open-Label Study of Dronabinol, a Cannabinoid Agonist, for Obsessive Compulsive Disorder and the Obsessive-Compulsive Spectrum Disorders Trichotillomania and Pathological Skin Picking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed study is to evaluate the efficacy and safety of dronabinol in
      individuals with obsessive-compulsive disorder (OCD) or the obsessive-compulsive spectrum
      disorders, trichotillomania (TTM) or pathological skin picking (PSP). Fifteen patients with
      OCD, TTM, or PSP will receive 12 weeks of open-label treatment with dronabinol. The
      hypothesis to be tested is that dronabinol will be effective and well tolerated in patients
      with these disorders. The proposed study will provide needed data on the treatment of a
      disabling disorder that currently lacks a clearly effective treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of twelve weeks of open-label dronabinol. All eligible study subjects will
      be started on open-label dronabinol 2.5mg/day for 3 weeks. The dose will be increased to
      5mg/day at visit 2 (Week 3), to10mg/day at visit 3 (Week 6), and to 15mg/day at Visit 4 (Week
      9) unless clinical improvement is attained at a lower dose (clinical improvement will be
      assessed by the investigator with respect to obsessive thoughts, urges and compulsive
      behaviors). Subjects will be seen every three weeks during the 12-week, open-label study. All
      efficacy and safety assessments will be performed at each visit. Subjects who are not
      compliant with their use of study medication (i.e. failing to take medication for three or
      more consecutive days) will be discontinued from the study.

      Laboratory testing, including liver function tests, a blood chemistry panel, and urine
      toxicology will be completed for subjects at baseline if in the opinion of the study
      physician the medical history of the subject warrants such tests for their safety. All
      females, regardless of age, will undergo a urine pregnancy test at screening and all subjects
      will be required to do a urine drug screen at the screening visit to test for drugs of abuse.

      At study conclusion, subjects will be given the option to continue on medication (via
      prescription) if covered by insurance, and will then be followed in our clinic or referred to
      another psychiatrist. All study subjects will be offered follow-up care with CBT and/or
      medication in our outpatient clinic (if covered by insurance) or be given a list of
      appropriate referrals in the community.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Massachusetts General Hospital Hairpulling Scale (MGH-HPS) Total Score</measure>
    <time_frame>Subjects were followed for their duration of participation in the study (12-weeks)</time_frame>
    <description>The MGH-HPS is a 7-item, self-report scale that rates urges to pull hair, actual amount of pulling, perceived control over behavior, and distress associated with hair pulling over the past seven days. Total possible score is a 28 indicating the highest level of severity out of a scale from 0-28.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Trichotillomania</condition>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Dronabinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>2.5mg-15mg by mouth once a day for twelve-weeks</description>
    <arm_group_label>Dronabinol</arm_group_label>
    <other_name>MARINOL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-65 years

          2. Obsessive-compulsive disorder (OCD), Trichotillomania (TTM), or Pathological Skin
             Picking (PSP) as the primary psychiatric diagnosis

          3. (If OCD) - Subject reports ≥two failed treatments using selective serotonin reuptake
             inhibitors (SSRIs) for their OCD

          4. Women's participation required negative results on a beta-human chorionic gonadotropin
             pregnancy test and stable use of a medically accepted form of contraception.

          5. Signed informed consent before entry into the study.

        Exclusion Criteria:

          1. Unstable medical illness or clinically significant abnormalities on laboratory tests
             or physical examination at screening visit

          2. Current pregnancy or lactation, or inadequate contraception in women of childbearing
             potential

          3. A need for medication other than dronabinol with possible psychotropic effects

          4. History of hypersensitivity to any cannabinoid or sesame oil

          5. Lifetime history of bipolar disorder type I or II, dementia, or schizophrenia as
             determined by the Structured Clinical Interview for DSM-IV

          6. Current (past 12-months) DSM-IV substance abuse or dependence

          7. Positive urine drug screen at screening

          8. Initiation of cognitive behavior therapy within 3 months prior to study baseline

          9. Baseline score of ≥ 17 on the Hamilton Depression Rating Scale (17-item HDRS

         10. Suicidality based on clinical interview

         11. History of head injury or neurological disorder (such as seizures)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon E Grant, JD, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ambulatory Research Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.impulsecontroldisorders.org/index.html</url>
    <description>Impulse Control Disorders Clinic - University of Minnesota</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <results_first_submitted>March 1, 2012</results_first_submitted>
  <results_first_submitted_qc>August 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 27, 2013</results_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chicago</investigator_affiliation>
    <investigator_full_name>Jon Grant</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Skin Picking</keyword>
  <keyword>OCD</keyword>
  <keyword>Trichotillomania</keyword>
  <keyword>Pathological Skin Picking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Trichotillomania</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dronabinol</title>
          <description>Dronabinol (Marinol) – 2.5mg–15mg by mouth once a day for twelve-weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dronabinol</title>
          <description>Dronabinol (Marinol) – 2.5mg–15mg by mouth once a day for twelve-weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.29" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Massachusetts General Hospital Hairpulling Scale (MGH-HPS) Total Score</title>
        <description>The MGH-HPS is a 7-item, self-report scale that rates urges to pull hair, actual amount of pulling, perceived control over behavior, and distress associated with hair pulling over the past seven days. Total possible score is a 28 indicating the highest level of severity out of a scale from 0-28.</description>
        <time_frame>Subjects were followed for their duration of participation in the study (12-weeks)</time_frame>
        <population>Mean score reported below is the endpoint MGH-HPS score (at 12-weeks or last-observation carried forward).</population>
        <group_list>
          <group group_id="O1">
            <title>Dronabinol</title>
            <description>Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Massachusetts General Hospital Hairpulling Scale (MGH-HPS) Total Score</title>
          <description>The MGH-HPS is a 7-item, self-report scale that rates urges to pull hair, actual amount of pulling, perceived control over behavior, and distress associated with hair pulling over the past seven days. Total possible score is a 28 indicating the highest level of severity out of a scale from 0-28.</description>
          <population>Mean score reported below is the endpoint MGH-HPS score (at 12-weeks or last-observation carried forward).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.71" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dronabinol</title>
          <description>Dronabinol (Marinol) – 2.5mg–15mg by mouth once a day for twelve-weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Light-headed / dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jon E. Grant</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-273-9800</phone>
      <email>grant045@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

